Post-earnings recap
Reported
Thu, Feb 17, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which is a positive sign for investors. However, the stock fell by 2.08%, likely due to a lack of revenue information and no guidance for the future. Investors may be concerned about the absence of specific future plans, despite the EPS beat.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | +54.67% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the company's future. They noted advancements in their drug development pipeline.
Management highlighted progress in their pipeline despite the loss.
They emphasized the importance of upcoming clinical trials.